Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis.
Clinical phenotypes
Idiopathic inflammatory myopathies
Inflammatory rheumatic diseases
Myositis-associated autoantibodies
Myositis-specific autoantibodies
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
16
02
2024
accepted:
05
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
The increased availability of myositis autoantibodies represents new possibilities and challenges in clinical practice (Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-64. https://doi.org/10.1136/annrheumdis-2017-211468 .). The aim of this study was to perform a retrospective data analysis of patient cases with positive myositis autoantibodies to analyse their significance in routine rheumatology practice. A monocentric analysis of all the orders used to determine myositis autoantibodies from July 2019 to May 2022 in the Department of Rheumatology, Krankenhaus Porz am Rhein, Cologne, Germany, was carried out. In the defined time interval, a total of 71,597 laboratory values for the antibodies mentioned above were obtained. A total of 238 different positive autoantibodies were detected in 209 patients. Idiopathic inflammatory myopathy was diagnosed in 37 patients (18%), and inflammatory rheumatic diseases other than idiopathic inflammatory myopathy were diagnosed in 90 patients (43%). No inflammatory rheumatic disease was diagnosed in 82 patients (39%). General clusters of clinical manifestations were observed. In our cohort, we were able to show that a relevant proportion of patients with positive myositis antibodies did not have idiopathic inflammatory myopathies or inflammatory rheumatic diseases. This finding indicates the importance of myositis autoantibodies in this group of patients. However, further studies on the course of symptoms and examination results in patients without inflammatory rheumatic diseases and with positive myositis antibodies are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
The increased availability of myositis autoantibodies represents new possibilities and challenges in clinical practice (Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-64. https://doi.org/10.1136/annrheumdis-2017-211468 .). The aim of this study was to perform a retrospective data analysis of patient cases with positive myositis autoantibodies to analyse their significance in routine rheumatology practice.
METHODS
METHODS
A monocentric analysis of all the orders used to determine myositis autoantibodies from July 2019 to May 2022 in the Department of Rheumatology, Krankenhaus Porz am Rhein, Cologne, Germany, was carried out.
RESULTS
RESULTS
In the defined time interval, a total of 71,597 laboratory values for the antibodies mentioned above were obtained. A total of 238 different positive autoantibodies were detected in 209 patients. Idiopathic inflammatory myopathy was diagnosed in 37 patients (18%), and inflammatory rheumatic diseases other than idiopathic inflammatory myopathy were diagnosed in 90 patients (43%). No inflammatory rheumatic disease was diagnosed in 82 patients (39%). General clusters of clinical manifestations were observed.
CONCLUSIONS
CONCLUSIONS
In our cohort, we were able to show that a relevant proportion of patients with positive myositis antibodies did not have idiopathic inflammatory myopathies or inflammatory rheumatic diseases. This finding indicates the importance of myositis autoantibodies in this group of patients. However, further studies on the course of symptoms and examination results in patients without inflammatory rheumatic diseases and with positive myositis antibodies are necessary.
Identifiants
pubmed: 39014499
doi: 10.1186/s13075-024-03368-9
pii: 10.1186/s13075-024-03368-9
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Informations de copyright
© 2024. The Author(s).
Références
Tomaras S, Feist E. Myositissyndrome. [Myositis]. Inn Med (Heidelb). 2023;64:152–63. https://doi.org/10.1007/s00108-023-01470-9 .
doi: 10.1007/s00108-023-01470-9
pubmed: 36705678
Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55. https://doi.org/10.1016/j.jaut.2019.04.001 .
doi: 10.1016/j.jaut.2019.04.001
pubmed: 30992170
pmcid: 6580360
Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014;5:69–75. https://doi.org/10.1007/s13317-014-0060-4 .
doi: 10.1007/s13317-014-0060-4
pubmed: 26000158
pmcid: 4386580
Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13:367–71. https://doi.org/10.1016/j.autrev.2014.01.022 .
doi: 10.1016/j.autrev.2014.01.022
pubmed: 24424190
pmcid: 3970575
Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018;16:5. https://doi.org/10.1186/s12948-018-0084-9 .
doi: 10.1186/s12948-018-0084-9
pubmed: 29540998
pmcid: 5840827
Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, Doria A. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15:335. https://doi.org/10.1007/s11926-013-0335-1 .
doi: 10.1007/s11926-013-0335-1
pubmed: 23591825
Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12:363–73. https://doi.org/10.1016/j.autrev.2012.06.004 .
doi: 10.1016/j.autrev.2012.06.004
pubmed: 22743033
Wen L, Chen X, Cheng Q, Nie L, Xu J, Yan T, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. Clin Rheumatol. 2022;41:3419–27. https://doi.org/10.1007/s10067-022-06291-z .
doi: 10.1007/s10067-022-06291-z
pubmed: 35859245
Platteel ACM, Wevers BA, Lim J, Bakker JA, Bontkes HJ, Curvers J, et al. Frequencies and clinical associations of myositis-related antibodies in the Netherlands: a one-year survey of all Dutch patients. J Transl Autoimmun. 2019;2:100013. https://doi.org/10.1016/j.jtauto.2019.100013 .
doi: 10.1016/j.jtauto.2019.100013
pubmed: 32743501
pmcid: 7388388
Lecouffe-Desprets M, Hémont C, Néel A, Toquet C, Masseau A, Hamidou M, et al. Clinical contribution of myositis-related antibodies detected by immunoblot to idiopathic inflammatory myositis: a one-year retrospective study. Autoimmunity. 2018;51:89–95. https://doi.org/10.1080/08916934.2018.1441830 .
doi: 10.1080/08916934.2018.1441830
pubmed: 29463118
Loarce-Martos J, Calvo Sanz L, Garrote-Corral S, Ballester González R, Pariente Rodríguez R, Rita CG, et al. Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity. Rheumatol Int. 2023;43:1101–9. https://doi.org/10.1007/s00296-023-05279-5 .
doi: 10.1007/s00296-023-05279-5
pubmed: 36763166
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64. https://doi.org/10.1136/annrheumdis-2017-211468 .
doi: 10.1136/annrheumdis-2017-211468
pubmed: 29079590
Saygin D, Glaubitz S, Zeng R, Bottai M, de Visser M, Dimachkie MM, et al. Performance of the 2017 EULAR/ACR classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review. Clin Exp Rheumatol. 2024;42:403–12. https://doi.org/10.55563/clinexprheumatol/vuc5py .
doi: 10.55563/clinexprheumatol/vuc5py
pubmed: 38436279
Bozzalla-Cassione E, Zanframundo G, Biglia A, Bellis E, Bozzini S, Codullo V, et al. Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clin Exp Rheumatol. 2022;40(Suppl 134):27–31. https://doi.org/10.55563/clinexprheumatol/bjb2gf .
doi: 10.55563/clinexprheumatol/bjb2gf
pubmed: 35349417
Troyanov Y, Targoff IN, Tremblay J-L, Goulet J-R, Raymond Y, Senécal J-L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Med (Baltim). 2005;84:231–49. https://doi.org/10.1097/01.md.0000173991.74008.b0 .
doi: 10.1097/01.md.0000173991.74008.b0
Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464–74. https://doi.org/10.1378/chest.10-0180 .
doi: 10.1378/chest.10-0180
pubmed: 21138882
Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:86. https://doi.org/10.1038/s41572-021-00321-x .
doi: 10.1038/s41572-021-00321-x
pubmed: 34857798
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85:41–5. https://doi.org/10.1054/bjoc.2001.1699 .
doi: 10.1054/bjoc.2001.1699
pubmed: 11437400
pmcid: 2363903
Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:523–32. https://doi.org/10.1002/art.33379 .
doi: 10.1002/art.33379
pubmed: 21953614
Ge Y, Lu X, Shu X, Peng Q, Wang G. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017;7:188. https://doi.org/10.1038/s41598-017-00240-6 .
doi: 10.1038/s41598-017-00240-6
pubmed: 28298642
pmcid: 5428032
Montagnese F, Babačić H, Eichhorn P, Schoser B. Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study. J Neurol. 2019;266:1358–66. https://doi.org/10.1007/s00415-019-09266-4 .
doi: 10.1007/s00415-019-09266-4
pubmed: 30840145
Hall JC, Casciola-Rosen L, Samedy L-A, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307–15. https://doi.org/10.1002/acr.21992 .
doi: 10.1002/acr.21992
pubmed: 23436757
Best M, Jachiet M, Molinari N, Manna F, Girard C, Pallure V, et al. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. J Eur Acad Dermatol Venereol. 2018;32:1164–72. https://doi.org/10.1111/jdv.14759 .
doi: 10.1111/jdv.14759
pubmed: 29237090
Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8. https://doi.org/10.1001/archdermatol.2011.52 .
doi: 10.1001/archdermatol.2011.52
pubmed: 21482889
Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72:449–55. https://doi.org/10.1016/j.jaad.2014.12.009 .
doi: 10.1016/j.jaad.2014.12.009
pubmed: 25595720
pmcid: 4351728
Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;12:210–7. https://doi.org/10.1016/j.autrev.2012.06.006 .
doi: 10.1016/j.autrev.2012.06.006
pubmed: 22771754
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16:689–701. https://doi.org/10.1038/s41584-020-00515-9 .
doi: 10.1038/s41584-020-00515-9
pubmed: 33093664